Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Cash from Financing Activities (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Cash from Financing Activities data on record, last reported at $192000.0 in Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 86.31% year-over-year to $192000.0; the TTM value through Dec 2025 reached $887000.0, down 99.14%, while the annual FY2025 figure was $887000.0, 99.14% down from the prior year.
  • Cash from Financing Activities reached $192000.0 in Q4 2025 per TRDA's latest filing, up from $8000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $101.4 million in Q2 2024 and bottomed at -$11000.0 in Q3 2024.
  • Average Cash from Financing Activities over 4 years is $7.8 million, with a median of $343500.0 recorded in 2025.
  • Peak YoY movement for Cash from Financing Activities: surged 38972.0% in 2023, then tumbled 102.99% in 2024.
  • A 4-year view of Cash from Financing Activities shows it stood at $358000.0 in 2022, then surged by 92.74% to $690000.0 in 2023, then soared by 103.19% to $1.4 million in 2024, then tumbled by 86.31% to $192000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $192000.0 in Q4 2025, $8000.0 in Q3 2025, and $337000.0 in Q2 2025.